Forgot Password?
Return to Course Listing

CME: Recognition and management of epidermolysis bullosa: what the clinician needs to know

Activity Description / Statement of Need:

In this online, self-learning activity:

Epidermolysis bullosa (EB) describes a group of rare, inherited skin diseases that are caused by mutations in at least 20 different genes with no known cure. These mutations can be inherited in an autosomal dominant or recessive manner leading to distinct clinical phenotypes. It is considered an orphan disease that affects about half a million people worldwide, with the National Epidermolysis Bullosa Registry estimating that the overall prevalence in the United States is 11.1 per one million live births.

Target Audience:

HCPs including: dermatologists and pediatric dermatologists; nurse practitioners, physician assistants, and pharmacists who treat dermatologic conditions; and those who otherwise care for or clinically encounter patients with epidermolysis bullosa.


Commercial Support Disclosure: This program is supported by an educational grant from Amryt Pharmaceuticals.

This activity is free of charge.


Release Date: February 28, 2024 -- Expiration Date: February 28, 2026

Faculty: M. Peter Marinkovich, MD

Agenda

Faculty Introductions, disclosures

Introductory content 

  • Epidemiology, incidence
  • Clinical features and diagnosis
    • Presentation, live expectancy, subtype prevalence
    • Major subtypes (EBS, JEB, DEB, & KEB)

Treatment of epidermolysis bullosa

  • Goals of care
  • Present and investigational pharmacotherapy, clinical trial findings, and guideline-recommended care
    • Wound management
    • Pain management
    • Nutrition
    • Extracutaneous complications 
    • Genetic consultation
  • Patient case(s) 

Summary, conclusions, and best practice recap.

Learning Objectives

By the end of the session the participant will be able to:

  • Summarize the healthcare burden unique to patients with EB and challenges to and best practices in its optimal identification and management.
  • Recall the present and emerging therapies for EB.
  • Formulate a treatment plan for a patient with EB.

Accreditation

ACCME Activity #202621403

ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABP MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

ABP MOC Credit Type: Lifelong Learning and Self-Assessment

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABP.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-24-004-H01-P. This is an Application (A)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: M. Peter Marinkovich, MD, Associate Professor, Department of Dermatology, Stanford University School of Medicine, has received financial compensation from Abeona Therapeutics, CastleCreek Biosciences, Krystal Biotech for grant/research support/paid investigator.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL discuss off-label uses of a commercial product.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Amryt Pharmaceuticals. 

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Present and novel approaches in the medical management of generalized pustular psoriasis: balancing out the therapeutic landscape

Melanoma - updates from the European Society for Medical Oncology (ESMO) 2023

Looking acne straight in the face: Treatment updates and challenges, with an emphasis on moderate to severe cases

Contemporary approaches and emerging therapies for the management of respiratory syncytial virus in infants and young high-risk children